- Published on
Pathology - Heparin-Induced Thrombocytopenia (HIT)
Heparin-induced thrombocytopenia (HIT) is a problem that can occur as a result of heparin treatment and can lead to the formation of blood clots in veins or, less commonly, arteries. The pathogenesis of this condition is characterized by the production of an immunological complex that is antigenic, leading to the development of a type II hypersensitivity reaction. Heparin molecules attach to the platelet-specific chemokine platelet factor 4 (PF4) and, as a result, trigger the creation of IgG (HIT antibodies). These antibodies then connect to the heparin-PF4 molecule, creating an immunological complex. The FcγIIa receptor found on platelets in the bloodstream attaches to the heparin-PF4-IgG immunological complex. As a result, macrophages in the spleen eliminate the platelets, leading to thrombocytopenia. Nevertheless, since both the PF4 and IgG components of the complex have the ability to attach to platelets, it is possible for a platelet that is carrying this immunological complex to adhere to another platelet while circulating in the bloodstream.
The process of cross-linking platelets through the immune complex results in more platelet aggregation and activation, which leads to the release of more PF4 capable of binding heparin. This, in turn, causes the creation of a paradoxical thrombus despite the presence of the anticoagulant. Arterial emboli resulting from HIT have become trapped in the microvasculature surrounding the first metatarsal in this patient, causing ischemia. The initial measure in the therapy process involves discontinuing the administration of heparin.
Heparin-induced thrombocytopenia (HIT) is a problem that can occur as a result of heparin treatment and can lead to the formation of blood clots in veins or, less commonly, arteries. The pathogenesis of this condition is characterized by the production of an immunological complex that is antigenic, leading to the development of a type II hypersensitivity reaction. Heparin molecules attach to the platelet-specific chemokine platelet factor 4 (PF4) and, as a result, trigger the creation of IgG (HIT antibodies). These antibodies then connect to the heparin-PF4 molecule, creating an immunological complex. The FcγIIa receptor found on platelets in the bloodstream attaches to the heparin-PF4-IgG immunological complex. As a result, macrophages in the spleen eliminate the platelets, leading to thrombocytopenia. Nevertheless, since both the PF4 and IgG components of the complex have the ability to attach to platelets, it is possible for a platelet that is carrying this immunological complex to adhere to another platelet while circulating in the bloodstream.
The process of cross-linking platelets through the immune complex results in more platelet aggregation and activation, which leads to the release of more PF4 capable of binding heparin. This, in turn, causes the creation of a paradoxical thrombus despite the presence of the anticoagulant. Arterial emboli resulting from HIT have become trapped in the microvasculature surrounding the first metatarsal in this patient, causing ischemia. The initial measure in the therapy process involves discontinuing the administration of heparin.
0 Comments
